Regeneron, A Leading U.S. Biotechnology Company, to Acquire 23andMe in Court-Supervised Sale

Core Viewpoint - 23andMe has entered into a definitive agreement to sell itself to Regeneron Pharmaceuticals for $256 million, ensuring compliance with privacy policies and consumer data protection [2][3][5]. Group 1: Transaction Details - The sale includes the acquisition of substantially all assets of 23andMe, specifically the Personal Genome Service (PGS) and Total Health and Research Services business lines, while excluding the Lemonaid Health subsidiary [3]. - The transaction is subject to court approval and is expected to close in the third quarter of 2025, following a court hearing scheduled for June 17, 2025 [5]. - The auction for the sale was completed on May 16, 2025, as part of 23andMe's Chapter 11 proceedings [5]. Group 2: Privacy and Compliance - Regeneron has committed to adhere to 23andMe's privacy policies and applicable laws, ensuring that customer personal data will be processed in accordance with existing consents and security measures [2][4]. - An independent Consumer Privacy Ombudsman will review the transaction's impact on consumer privacy and report to the court by June 10, 2025 [4]. Group 3: Company Statements - Mark Jensen, Chair of 23andMe's Board, expressed satisfaction with the transaction, highlighting its potential to maximize business value while protecting customer privacy [3]. - George D. Yancopoulos from Regeneron emphasized the company's commitment to safeguarding genetic data and enhancing 23andMe's mission to help individuals understand their DNA [4].